Pre-clinical
Preclinical studies have allowed us to identify the potential of IGC-AD1 to be an AD-modifying drug. The combination of the active ingredients at low, non-toxic concentrations was shown to reduce Aβ aggregation in N2aAβPPswe cells, maintain APP levels, and enhance mitochondrial function in a dose-dependent manner.
Pre-clinical
Study results
The pre-clinical studies tested the API in IGC-AD1 on Alzheimer’s cell lines and Alzheimer’s mouse models and found that it had the potential to be a disease modifying drug that could:
-
Inhibit the formation of neurofibrillary tangles
-
Inhibit the formation of plaques.
-
Enhance mitochondrial functioning.
-
Improve spatial memory.
Pre-clinical studies:
Detailed scientific results
Aβ production & Aggregation
Aβ Monomeros
APP Levels
Spatial Memory
Neurotoxicity
The API in IGC-AD1 reduces Aβ40 peptide production and Aβ42 aggregation in Alzheimer’s cell lines.
Representation of Cao et al., 2014
